Journal for Immunotherapy of Cancer
-
Publication Venue For
- Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.. 7:218. 2019
- Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.. 7:142. 2019
- Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.. 7:104. 2019
- Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.. 7:84. 2019
- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.. 7:80. 2019
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.. 7:27. 2019
- Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.. 7:18. 2019
- White paper on microbial anti-cancer therapy and prevention.. 6:78. 2018
- Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.. 6:77. 2018
- Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.. 6:54. 2018
- Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.. 6:51. 2018
- Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.. 6:9. 2018
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.. 6:4. 2018
- Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.. 5:102. 2017
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.. 5:44. 2017
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.. 4:52. 2016
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.. 4:89. 2016
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.. 4:15. 2016
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.. 4:44. 2016
- Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.. 4:34. 2016
- Combination of IFNα and poly-I: C reprograms bladder cancer microenvironment for enhanced CTL attraction. 3. 2015
- Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.. 3:13. 2015
- Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.. 3:50. 2015
- Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients.. 3:P444-P444. 2015
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.. 3:19. 2015
- Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771.. 3:P357-P357. 2015
- Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.. 2:20. 2014
- Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.. 1:21. 2013
- Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.. 1:P129-P129. 2013
- A HSP-TLR-Wnt5a paracrine signaling axis drives CXCR2 ligand recruitment of myeloid-derived suppressor cells and represents a novel adaptive resistance mechanism to anti-PD-1 antibody therapy 2017
- Generation of therapeutic RNAs to induce immunogenic cell death and interferon expression in cancer cells 2017
- Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab +/- ipilimumab: CheckMate 142 2017
- PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus 2017
- Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy
- The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.